CONICETExecutive Unit · CONICET · UNT · SIPROSA

Biomedical research from Tucumán

We study how neurodegenerative diseases begin and develop new tools to detect and treat them. We do this together with health-care teams, research groups and technology-based companies.

Institute for Research in Applied Molecular and Cellular Medicine · CONICET, UNT and SIPROSA

Research · Teaching · Technology transfer

CONICET National University of Tucumán Provincial Health System, Tucumán Ministry of Public Health

News

IMMCA researchers at the Neurotoxicity Society meeting in Montevideo

IMMCA at the Neurotoxicity Society meeting

In Montevideo we presented our work alongside some 200 specialists from around the world.

View on Instagram
Biochemistry students visiting IMMCA

We opened the institute to Biochemistry students

During the 27th Augusto Palavecino Scientific Conference, students and graduates learned about the research in our laboratories.

View on Instagram
Álvaro Luna Mercado working in the laboratory

Aptamers: training in Uruguay

Álvaro Luna Mercado took part in the meeting of the Ibero-American Aptamer Network (REDIBA) and in an international course of the Argentine-Brazilian Biotechnology Center.

View on Instagram
Valentina Budeguer at the microscope

C. elegans travels to Chile

Valentina Budeguer, a doctoral student at IMMCA, is taking part in the international course “Small Brains, Big Ideas” in Las Cruces.

View on Instagram
Confocal microscopy image

Our services, now on PLASENOA

CONICET NOA Sur launched its services platform for northwestern Argentina. IMMCA offers five technology services there.

View on PLASENOA
Awards ceremony at the School of Biochemistry, Chemistry and Pharmacy

Recognition for Lourdes Henzelmann

The UNT School of Biochemistry, Chemistry and Pharmacy recognized her work, which was selected for the AUGM Young Researchers Conference in Brazil.

View on Instagram
Laura Guayán next to her poster at the FALAN congress

Laura Guayán at the FALAN Neuroscience School

She was selected for the first Neuroscience School and presented her work at the FALAN congress, together with Valentina Budeguer.

View on Instagram
IMMCA presentation on stage at ExpoCon 2026

IMMCA at ExpoCon 2026

We told the story of how early questions about protein aggregation led to new technologies for neurodegenerative diseases.

View on Instagram
Rodrigo Tomas Grau, AD/PD 2027 Ambassador

Rodrigo Tomas Grau, AD/PD 2027 Ambassador

He was selected as an Ambassador for “Voices of AD/PD”, one of the leading international conferences on Alzheimer’s and Parkinson’s disease.

View on Instagram
Students at a Science Week activity at IMMCA

Science and Technology Week

We welcomed students with stands and posters, and our director gave a talk at the Instituto Técnico de Aguilares.

View on Instagram
IMMCA researcher explaining the new article on Pegasus

New article: optimizing Pegasus

We redesigned the linker that joins the two parts of Pegasus and obtained three new molecules that retain its ability to interfere with alpha-synuclein aggregation.

View on Instagram
IMMCA members, patients and families in front of the Casa Histórica lit up in red

Tucumán lit up in red for World Parkinson’s Day

An initiative of IMMCA together with UNT, CONICET, the Ministry of Public Health, the City of San Miguel de Tucumán and Hospital Padilla.

Read on CONICET NOA Sur

Ministry of Health approves the Pegasus license

Resolution 1204/SPS/25 approves the agreement with SkyBio LLC and recognizes IMMCA as the site where the compound was developed.

Read on the Ministry website

BrinDx wins first prize at IB50K

The startup born at IMMCA won the Instituto Balseiro business plan competition, among 34 projects from across Argentina.

Read on IN Tucumán

A new molecule against Parkinson’s disease is patented

In preclinical studies, Pegasus, designed at IMMCA with UBA and SkyBio, improved symptoms and protected neurons.

Read on CONICET

World Parkinson’s Day

What we know about the disease today, and how the institute is working to diagnose it earlier.

Read on immca.conicet.gov.ar
Certificate of the Honorable Mention awarded to IMMCA by the Chamber of Deputies

Honorable Mention from the Chamber of Deputies

Recognition of IMMCA’s contribution to science and innovation, and of its commitment to public health during the COVID-19 pandemic.

The story of InmunoCoviTuc

A serological test developed in Tucumán that delivered strong results during the pandemic.

Read on CONICET

Sputnik V antibodies last at least six months

A study with IMMCA participation confirmed how long the response lasts after vaccination.

Read on CONICET

A successful model of technology transfer

The director presented the IMMCA case: three parent institutions and close ties with the private sector.

Read on immca.conicet.gov.ar

Visit of the Ambassador of France

Cooperation with French teams on Parkinson’s and Alzheimer’s disease.

Read on immca.conicet.gov.ar

A young institute, founded in 2018.

Basic science, clinical research and partnerships with industry, backed by CONICET, UNT and SIPROSA.

30Scientific articles published since 2018
2Licensed international patents
15Researchers, fellows and research support staff
13Countries of our international co-authors

Figures as of 17 November 2026. The articles are those published since the institute was created; the library also includes earlier work by the team.

Official name
Instituto de Investigaciones en Medicina Molecular y Celular Aplicada (Institute for Research in Applied Molecular and Cellular Medicine)
Type
CONICET Executive Unit
Parent institutions
CONICET · UNT · SIPROSA
Director
Dr. Rosana N. Chehín
Deputy director
Dr. César Luis Ávila
Address
Pasaje Dorrego 1080, San Miguel de Tucumán
Official profile
CONICET BICyT
IMMCA researchers, fellows and staff in the protein production laboratory
IMMCA protein production and purification laboratory, San Miguel de Tucumán.

We started as a small protein biophysics group. When our questions moved closer to Parkinson's disease, we joined forces with the neurologists at Hospital Padilla. That alliance gave rise to an institute devoted to translational medicine.

How we got here

2003

Protein biophysics

A group is formed at INSIBIO to study amyloid aggregation from a physical perspective, still without cell cultures or in vivo models.

2010

From physics to neurobiology

The group applies biophysics to the study of Parkinson's disease, and the neurologists at Hospital Padilla join in.

2016

Request to create the institute

In November the formal request is submitted, taking the Paris Brain Institute as a model and including a 480 m² building project.

2017

An antibiotic against Parkinson's disease

Scientific Reports publishes how doxycycline remodels toxic alpha-synuclein oligomers. The study is widely covered by the national media.

2018

IMMCA is born

On May 23, CONICET, UNT and the Tucumán Ministry of Public Health sign the framework agreement. A memorandum with SkyBio is signed the same day.

2019

Pegasus agreement

CONICET, UNT, SIPROSA, FCEN-UBA and SkyBio sign an agreement to develop a new carrier to deliver dopamine to the central nervous system.

2020

Science during the pandemic

The institute places its platforms at the service of public health: diagnosis, immunity and the neurological sequelae of SARS-CoV-2.

2021

A biosensor for Parkinson's disease

Aristaeus agreement: a diagnostic device based on tetracycline derivatives that bind to a biomarker of the disease.

2024

Pegasus: patent granted

La patente del candidato a fármaco para Parkinson se aprueba en Estados Unidos y en la Unión Europea, y sigue en trámite en otros seis países. En 2025 se aprueba su licencia a SkyBio LLC.

2026

Pegasus: preclinical stage complete

Pegasus completes its preclinical evaluation, in cell and animal models, and the pre-IND package for the FDA is ready. It has not been tested in people yet.

2027

Meeting with the FDA

Scheduled for February: the step before requesting authorization for first-in-human studies.

Why IMMCA was created

From the lab to the clinic, and from the clinic to the lab.

IMMCA was founded in Tucumán to bring biomedical research closer to the needs of the public health system. Questions that arise in patient care help guide work in the lab. In turn, lab findings can become new diagnostic tools and therapeutic strategies. This two-way exchange is the basis of translational medicine.

The National University of Tucumán, CONICET and the Tucumán Provincial Health System (SIPROSA) created the institute building on the biomedical research teams and projects already active in the province. SIPROSA provided the site at Dorrego 1080, where the first stage of the building was constructed, with spaces for cell culture, confocal microscopy and protein production.

Since then, IMMCA has expanded its facilities and acquired equipment to study disease mechanisms, develop new technologies and assess their potential use in health care.

The model: the Paris Brain Institute (ICM) at the Pitié-Salpêtrière Hospital, Paris

Scientific research

UNT and CONICET contribute the researchers, the training of fellows and the underlying scientific questions.

Health system

SIPROSA contributes the building, the services and something even more valuable: patients' real-world problems and clinical studies.

Technology-based companies

Private partners such as SkyBio fund development and bring the results to market: new drugs and diagnostic methods.

Translational medicine science, healthcare and industry working together

Our goals

  1. 01Prioritize projects that bring together different biological and biomedical specialties.
  2. 02Train multidisciplinary researchers and offer opportunities for undergraduate and graduate theses.
  3. 03Help the health system adopt new technologies.
  4. 04Redirect basic research when the health system needs it, as happened during the pandemic.
  5. 05Sustain international collaborations and publish to the highest standards.
  6. 06Contribute our equipment and expertise to clinical research, and strengthen public-private partnerships.

Institutional development project

Three areas of work that have guided the institute since its first director.

Area 1

Institutional management

  • A governing board and dedicated committees for finance, biosafety, infrastructure, technology transfer and communication.
  • Quality management under ISO 17025 and environmental management under ISO 14001.
  • Continued growth in space and equipment so that all groups can work together.
  • Partnerships with public and private organizations.
Area 2

Science and training

  • A strategic plan reviewed every year.
  • Participation in translational health research networks.
  • Regular meetings with healthcare teams to identify joint projects.
  • Weekly seminars with invited speakers from Argentina and abroad.
  • Support for projects led by early-career researchers.
Area 3

Partnerships and technology transfer

  • Expand the services of the cell culture and neuroprotection assay platform.
  • Deepen agreements with companies to develop patentable products.
  • Teach fellows to identify results worth protecting.
  • Foster health startups founded by young scientists.

Infrastructure and equipment

Our own laboratories at Dorrego 1080, San Miguel de Tucumán, with advanced equipment for molecular and cell biology.

Cell culture

A room with an airlock and HEPA-filtered positive pressure, for work with cell lines such as SH-SY5Y, HEK and BV2.

  • Class II biological safety cabinet
  • Self-sterilizing CO₂ incubator
  • Zeiss Primovert phase-contrast microscope

Microscopy

High-resolution imaging of cells, tissues and model organisms.

  • Zeiss LSM 800 confocal microscope
  • Zeiss Axio Vert inverted fluorescence microscope with incubation chamber

Protein production

Expression, cell disruption and purification of recombinant proteins such as alpha-synuclein and tau.

  • ÄKTA pure FPLC system
  • LM20 Microfluidizer
  • Sorvall Lynx 4000 refrigerated superspeed centrifuge
  • Bio-Rad Mini-PROTEAN electrophoresis

Biophysics and spectroscopy

Protein aggregation, particle size and optical microplate assays.

  • Horiba Fluoromax-4 spectrofluorometer
  • TECAN Spark multimode reader
  • Dynamic light scattering and zeta potential
  • DeNovix DS-11 microvolume spectrophotometer

Laboratory support

Sample storage and material preparation.

  • −85 °C ultra-low freezer
  • Eppendorf thermomixers
  • Ultrapure water system
  • Autoclave, glassware washer and drying oven

Open to other groups

Researchers, companies and organizations can use this equipment through our technology services.

See our services
Portrait of Dr. Rosana Chehín wearing an IMMCA lab coat in the laboratory
Director, appointed by competitive selection in 2021 ORCID

Dr. Rosana Chehín

Director of IMMCA

CONICET Principal Researcher and Full Professor of Biological Chemistry at the National University of Tucumán. She graduated in Biochemistry at the top of her class and earned her PhD in Biochemistry with the highest distinction.

She trained in protein spectroscopy at the University of the Basque Country and was a visiting professor at Université Paris-Est. She served as UNT Secretary of Science, Art and Technological Innovation, and is currently a member of the Tucumán Academy of Medical Sciences and of the editorial board of Frontiers in Aging Neuroscience.

52articles in international journals
3patents as inventor over her career
9doctoral theses supervised
+30fellows and researchers trained
2021Director of IMMCA (CONICET, UNT, SIPROSA)
2022Full Professor, Biological Chemistry II, FBQF, UNT
2019Governing Board, CCT CONICET NOA Sur
2018CONICET Principal Researcher
2014Secretary of Science, Art and Technological Innovation, UNT (until 2016)
1991Biochemist, UNT. Top of her class
1995PhD in Biochemistry, UNT. Grade: 10/10
1996Postdoctoral fellowship, University of the Basque Country (Basque Government)
2011Visiting professor, Glycanes Research Team, Université Paris-Est
2013Research stay at INSERM, Paris Brain Institute (ICM), Paris
2025Optimization of Pegasus for clinical application (CONICET PIETR)
2024New diagnostic technologies for the public health system (Mincyt and Minsal)
2022France Alzheimer: multimodal tetracyclines, Argentine node
2022Diagnostic test for neurodegenerative diseases (PITES)
2022Immuno-radiotracers for premotor diagnosis of Parkinson's disease (PICT)
Ponce Hornos Award Argentine Biophysical Society, 2009 Best Technological Innovation in Health NOATIC Awards, 2013 D. F. Sarmiento Honorable Mention Argentine National Senate, 2018 Scientific Merit Mention Argentine National Senate, 2021 J. B. Alberdi Honorable Mention Argentine Chamber of Deputies, 2022 Best Doctoral Graduate Argentine Federation of University Women, 1996
What we do

Research lines

We aim to diagnose earlier and treat better Parkinson's disease and other neurodegenerative disorders.

Each line links basic science with results that go beyond the laboratory: patents, kits, licenses and services. Lines marked VT involve technology transfer partnerships with companies or institutions.

Aggregation modelUnder normal conditions, alpha-synuclein is a soluble protein with no defined structure. In Parkinson’s disease it adopts a beta-sheet-rich conformation, assembles into oligomers and forms amyloid fibrils that act as seeds and spread misfolding. These fibrils are the main component of Lewy bodies.
Lewy body stained for alpha-synuclein in a neuron
01VT

New drugs for Parkinson's disease

We redesign tetracyclines, well-known antibiotics, so that they protect neurons without acting as antibiotics. This is how Pegasus was born, a drug candidate currently in the preclinical stage.

  • Patent WO2022167954
  • Licensed to SkyBio
  • FCEN-UBA · ICM/CNRS
See the Pegasus case
PC-12 neuron imaged by multicolor fluorescence microscopy
02VT

Early diagnosis

We want to detect the disease before motor symptoms appear: a biosensor, new PET radiotracers and the RT-QuIC technique using locally produced reagents, with the goal of applying it to blood samples.

  • Patent WO2023214381
  • Startup BrinDx
  • INSIBIO · FCEN-UBA · SkyBio
Meet BrinDx
Cultured cells with labeled mitochondria and cytoskeleton
03

How neurons become diseased

We study how alpha-synuclein, tau and other proteins form toxic aggregates, using new experimental models, and the genetics of Parkinson's disease in Latin America.

  • LARGE-PD consortium
  • Cell models and C. elegans
04VT

Infection and immunity

During the pandemic we placed the institute at the service of public health with our own SARS-CoV-2 antibody test. Today we study the effects of the virus on the brain.

  • InmunoCoviTuc ELISA kit
  • Tucumán Ministry of Health
05VT

Proteins and biomaterials

We produce alpha-synuclein and tau as monomers, fibrils and fluorescent fibrils for other laboratories, and we use amyloid fibrils as enzyme supports for biodiesel, wine and olive oil applications.

  • Research-grade proteins
  • Industrial applications
In progress · Early diagnosis

RT-QuIC: an assay to detect misfolded alpha-synuclein

A biomarker is a measurable signal in the body that shows a disease is present or progressing. Most neurological biomarkers in use today, such as NfL, GFAP or pTau, measure how much protein there is, and they can also rise for other reasons.

RT-QuIC, a seed amplification assay (SAA), measures something else: whether the sample contains misfolded alpha-synuclein able to pass its shape on to other proteins, the biochemical hallmark of Parkinson’s disease. It can detect one aggregate among a billion normal molecules.

Concentration biomarkersNfL · GFAP · pTau

They measure amount or damage. Indirect.

Functional biomarkerRT-QuIC (SAA)

Detects the protein form that spreads the disease.

How it developed worldwide

  1. 1997

    Lewy bodies, the typical lesion of Parkinson’s, are found to be made of alpha-synuclein.

  2. 2016

    First detection of aggregated alpha-synuclein in cerebrospinal fluid using RT-QuIC.

  3. 2023

    It is detected in blood, a key step toward a simpler test.

  4. 2024

    The FDA issues a letter of support for the alpha-synuclein assay as a biomarker for research.

What we do at IMMCA

  1. 01 · Achieved

    OAS project

    It allowed us to move forward with implementing a diagnostic test for neurodegenerative diseases.

  2. 02 · Achieved

    Our own reagent

    The assay needs recombinant human alpha-synuclein, which costs about USD 1,020 per milligram. We produce it at IMMCA: 100 mg per month.

  3. 03 · Ongoing

    Validation in cerebrospinal fluid

    We set up the assay with locally produced reagents and, together with ANLIS-Malbrán, are validating it in cerebrospinal fluid, the sample type where the technique is best established. In parallel we are implementing quality management systems.

  4. 04 · Ongoing

    Exploring blood

    Through a CONICET PIETR project we are exploring the use of RT-QuIC on neuron-derived extracellular vesicles isolated from plasma. This line is still under development: it is not an available test yet.

We also offer technology services using our equipment and support startups such as BrinDx.

Our team

Each name links to the person's official CONICET profile, with their research topics, projects and publications.

IMMCA members in lab coats in the institute's cell culture laboratory
7Researchers
4Fellows
2Research support staff

Fellows

Research support staff

Source: IMMCA's official profile on CONICET (BICyT). The team also includes UNT faculty, thesis students and undergraduate students.

A day at the institute

Our team

Beyond the lab

Besides doing science, we have fun. We're competitive, a little crazy and not afraid of looking silly: end-of-year parties, challenges, dancing and plenty of humor. That's who we are, inside and outside the lab.

Fellowships and theses

Join IMMCA

If you are interested in doing your undergraduate thesis, PhD or postdoc in neuroscience, protein biophysics or health biotechnology, we would like to hear from you.

01

Undergraduate thesis

For advanced students of Biochemistry, Biotechnology and related degrees. You can apply for CIN or CIUNT undergraduate research scholarships.

02

PhD

With CONICET doctoral fellowships, including those for strategic topics, through the UNT doctoral program.

03

Postdoc

With CONICET postdoctoral fellowships, to join an ongoing research line or propose your own.

Why train here

  • Close to the clinic. We work with physicians and healthcare professionals on questions that arise from clinical practice.
  • Advanced equipment. Confocal microscopy, FPLC, light scattering and cell culture for your own project.
  • International networks. We publish with groups in 13 countries, including the Paris Brain Institute.
  • From science to industry. Two international patents and the startup BrinDx were born here.

Want to join us? Tell us what you're interested in and we'll guide you.

Contact us

Scientific output

Three decades of work by the group, including papers from before the institute was created in 2018. That is why there are more than the 30 articles counted in the IMMCA figures. Open-access papers can be read right here; the rest, in the journal.

Loading publications
Since 2018

7researchers

We are a small team. This is what we have produced since 2018.

  • 30Articles in international journals
  • 4.3Articles per researcher
  • 3.3Articles per year
  • 7Doctoral theses defended
  • 2Licensed international patentsPegasus and Aristaeus
  • 3R&D agreements
  • 7STAN technology services
  • 2Book chapters

We also have a regular presence at national and international conferences, with presentations and invited talks.

Averages over 7 researchers and 9 years (2018–2026). Institute profile at CONICET

Co-authors in 13 countries

  • France
  • Brazil
  • Spain
  • Germany
  • United Kingdom
  • Italy
  • United States
  • Chile
  • Peru
  • Colombia
  • Mexico
  • Puerto Rico
  • Guadeloupe
Innovation

Knowledge that gets patented

Two international patent families, with SIPROSA as co-owner alongside CONICET, UNT, UBA and SkyBio LLC.

Pegasus (DAD9) · priority date Feb 3, 2021

A drug candidate for Parkinson's disease

Designed and evaluated at IMMCA after more than a decade of research into the molecular basis of the disease, and synthesized at UBA.

Licensed to SkyBio LLC · preclinical stage
USApproved
European UnionApproved
JapanPending
KoreaPending
AustraliaPending
BrazilPending
CanadaPending
IsraelPending
Aristaeus · WO 2023/214381

Early diagnosis of neurodegenerative diseases

A biosensor based on tetracycline derivatives that bind to aggregated alpha-synuclein. National phase applications filed in eight countries. Licensed to SkyBio LLC.

Favorable office action in the US, November 2026
Pegasus, step by step
  1. 2021Patent application
  2. 2024Approved in the US and the EU
  3. 2025Licensed to SkyBio LLC
  4. 2026Preclinical stage completed and pre-IND package ready
Our most advanced project

The Pegasus pathway

Pegasus (DAD9) is a drug candidate for Parkinson's disease designed at IMMCA. It has not yet reached patients: it has completed the preclinical stage and is now preparing to request FDA authorization for first-in-human studies.

Patent
Granted in the United States and the European Union. Pending in six other countries.
Licence
Exclusive to SkyBio LLC since 2025, with SIPROSA, CONICET, UNT and UBA as co-owners.
Evidence
Preclinical stage complete, in cell and animal models. It has not been tested in people yet.
Next step
Pre-IND meeting with the FDA, scheduled for February 2027.

Status as of 17 November 2026

  1. 01

    Synthesis and protection

    Scaled-up synthesis with GMP certification. Patents in 8 jurisdictions and an exclusive license to SkyBio LLC.

  2. 02

    Evaluación preclínica

    Toxicity, safety pharmacology, pharmacokinetics, drug interactions and behavioural studies in C. elegans, mice (including the A53T model), rats and beagle dogs. Formulation tested across all evaluated species.

  3. We are here 03

    Preparación clínica

    The pre-IND package for the FDA is complete, with the meeting scheduled for February 2027. It is the step before requesting authorisation for the first studies in people.

Step by step

More than a decade of research, from protein biophysics to a drug candidate.

Two problems in one disease

In Parkinson's disease, alpha-synuclein forms toxic aggregates and dopamine-producing neurons are lost. Dopamine itself, in turn, does not reach the brain well when given as a drug.

From tetracyclines to a new molecule

Since 2017 we have studied how doxycycline transforms alpha-synuclein aggregates. Building on that knowledge, we designed a tetracycline without antibiotic activity linked to dopamine: DAD9, Pegasus.

BiophysicsMedicinal chemistryFCEN-UBA

A dual action

In experimental models, Pegasus interferes with alpha-synuclein aggregation and seeding, oxidative stress and neuroinflammation, while activating dopamine receptors without forming the toxic derivatives of free dopamine.

Disease-modifyingSymptomatic

Evaluación preclínica

Acute and sub-chronic toxicity, safety pharmacology, pharmacokinetics and ADME, drug–drug interactions, route of administration and behavioural studies, in C. elegans, mice (including the A53T Parkinson’s model), rats and beagle dogs. The studies were carried out together with KeifeRX, Georgetown University and Eurofins.

KeifeRXGeorgetownEurofinsFormulation ready

Protection and transfer

International patent approved in the US and the EU, and pending in other countries. Licensed to SkyBio LLC, as approved by Resolution 1204/SPS/25 of the Ministry of Public Health.

USEuropean UnionSkyBio LLCSIPROSA

Toward the clinic

The pre-IND package is complete and the meeting with the FDA is scheduled for February 2027. The next challenge is to determine whether this profile translates into a benefit for patients.

FDA · pre-INDFebruary 2027
Startups born at IMMCA

BrinDx

A technology-based company working toward earlier diagnosis of neurodegenerative diseases, starting with Parkinson's disease.

It was founded when members of the institute decided to create a company to bring their developments to market. Its team brings together UNT students and graduates with CONICET and SIPROSA researchers. It works on nano-radiotracers for diagnostic imaging, and offers recombinant proteins and assay kits for research. Together with the institute, it seeks to adapt the RT-QuIC technique, using locally sourced reagents, so that it works in blood.

  • 1st prize, IB50K 2024Instituto Balseiro business plan competition, among 34 projects from across Argentina
  • Angel investmentIts first investor was a French entrepreneur living with Parkinson's disease
  • Next stepPatenting its nanobodies

Technology services

CONICET High-Level Technology Services (STAN) for companies, public agencies and R&D institutions. Five of them are listed on PLASENOA, the CONICET NOA Sur services platform.

We also sign R&D agreements with companies, such as those with SkyBio and BACON SAIC. View on PLASENOA · View on CONICET

Request a service

Tell us what you need and we will reply with availability, terms and a quote.

Services coordinator
Sabrina Sequeira

Or write to her directly…

Please enter your name.
Please check your email address: something is missing or incorrect.
Please tell us what you need.

Your email program opens with the enquiry already written. Check it and send it from there.

IMMCA members, patients and families in front of the Casa Histórica de la Independencia lit up in red, on April 11, 2026
Community engagement

We study Parkinson's disease with the people who live with it in mind.

April 11, 2026 · World Parkinson's Day

Tucumán lit up in red

At IMMCA's initiative, the Casa Histórica de la Independencia, the Bicentennial Monument, the UNT Rectorate, the MUNT, the Virla Cultural Center and other buildings in the province were lit up in red at 7 p.m., as in many cities around the world.

Red is the color of the tulip, the international symbol of the disease. Researchers, fellows, patients, families and caregivers gathered in front of the Casa Histórica for readings, music and dance. We asked the community to wear something red and to share the message: a disease that is often silent needs to be seen.

“Raising awareness is a fundamental step toward improving the quality of life of people with Parkinson's disease.”Rosana Chehín, Director of IMMCA
A couple dances tango in front of the Casa Histórica lit up in red
A musician plays the bombo legüero drum next to the wall lit up in red
Local residents dance on the sidewalk outside the Casa Histórica
Group photo in front of the door of the Casa Histórica

How we shared it

The call was shared on the social media channels of Hacé Click and Medios UNT. It was an initiative of IMMCA together with UNT, CONICET, the Ministry of Public Health, the City of San Miguel de Tucumán and Hospital Padilla.

In front of the Casa Histórica, patients, families, healthcare professionals and researchers shared a symbolic embrace, to the tango of Bondi Milonguero Tucumán. The following Monday, Hospital Padilla hosted a day with specialists and proposals to improve the quality of life of people living with Parkinson's disease.

View on Instagram
@immca.lab and Bondi Milonguero
View on Instagram
Hacé Click and @immca.lab
View on Instagram
Medios UNT

Red Argentina de Parkinson

We are part of the Red Argentina de Parkinson (Argentine Parkinson's Network), with which we share activities such as World Parkinson's Day in Tucumán.

Talks for patients and families

We explain, in plain language, what is being researched and what is known today: from the “Café con ALMA” meetings in 2019 to the Asociación Parkinson Neuquén congress in 2024.

Genetics of Parkinson's disease in Latin America

We take part in the LARGE-PD consortium, which studies the genetics of the disease in Latin American populations.

Public science, shared with the public

Research in a public laboratory is funded by the whole of society. Sharing it is part of the job.

175

media appearances since 2020, in local and national press, TV, radio, social media and official channels.

0 staff dedicated to communications. Every story is told by our own researchers and fellows.
Where IMMCA appeared, 2020 to 2026
  • National media51
  • Tucumán media37
  • TV, radio and video27
  • CONICET and UNT27
  • Social media19
  • Government and Ministry12
  • International2

Source: IMMCA press archive and web search, November 2026.

La NaciónClarínInfobaePágina/12TélamTNRadio NacionalLa GacetaTiempo ArgentinoEl DestapeRío NegroDiario de CuyoLa CapitalIntraMedCanal 10CONICET

@immca.lab in the last 90 days

The most-followed account among CONICET institutes in northwestern Argentina, run by our own fellows with two posts a week.

160,068views+50.6% vs. previous quarter
32,094accounts reached9 times the number of followers
3,506followers+11.8% in 90 days

Let's do research together.

Scientific collaborations, services, fellowships or press: write to us or visit the institute.

Instagram@immca.lab
Parent institutionsCONICET, National University of Tucumán and Provincial Health System